MORE►
SKYCLARYS
Reata CEO Warren Huff [DI; Source photo: Reata]
Biogen To Acquire Plano-Based Biotech Reata Pharmaceuticals
by Lance Murray | Jul 28, 2023
Founded in 2002, rare disease drugmaker Reata has made significant advances in therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. The company's FDA-approved SKYCLARYS is the first and only approved treatment in the U.S. for Friedreich’s ataxia, a genetic nervous system disorder.
by Lance Murray |
Mar 2, 2023
The FDA approval is not only a first for Reata's treatment of ultra-rare disease Friedreich's Ataxia. It's a first in the company's history, reports FiercePharma. On the news, Reata’s stock skyrocketed nearly 200% Wednesday, according to the Dallas Morning News, which cited an estimate that the drug will create a revenue stream in excess of $1 billion.
MORE►
